Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioCardia, Inc. (NASDAQ: BCDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease, BioCardia uses these filings to report on financial results, governance matters, clinical and regulatory milestones, and capital markets activity.
Here you can review current reports on Form 8-K, which BioCardia uses to announce material events such as quarterly financial results, progress in its CardiAMP and CardiALLO clinical programs, enrollment updates in the CardiAMP HF II Phase 3 trial, consultations with Japan’s PMDA, leadership and board changes, and notices related to Nasdaq listing compliance. These filings often incorporate or reference press releases that detail developments in the company’s investigational therapies and enabling technologies like the Helix delivery system and Morph vascular navigation platform.
Investors can also consult proxy materials such as the definitive proxy statement on Schedule DEF 14A, which outlines proposals for director elections, amendments to the equity incentive plan, auditor ratification, and advisory votes on executive compensation, as well as information on board structure and corporate governance. Periodic reports on Forms 10-K and 10-Q, referenced in company communications, provide broader context on risk factors, financial condition, and the status of clinical programs.
Stock Titan enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand the significance of lengthy filings, including complex sections on clinical trial status, equity financings, and listing compliance. Real-time updates from EDGAR, along with structured access to items such as results of operations, other events, and shareholder meeting notices, make this BCDA filings page a focused resource for analyzing BioCardia’s regulatory and corporate disclosures.
Simon H. Stertzer, a director of BioCardia, Inc. (BCDA), reported purchases and related holdings on Form 4. He participated in a public offering that closed on 09/19/2025, purchasing 398,400 shares of common stock at $1.25 per share and receiving 398,400 warrants exercisable into one share each at $1.25. The warrants are dated 09/19/2025 and expire 09/20/2027. After the reported transactions the filing shows 591,054 shares beneficially owned indirectly by entities tied to the reporting person, and several pre-existing holdings across trusts and LLCs are disclosed. The Form 4 is signed by power of attorney on 09/23/2025.
BioCardia insider purchase reported on Form 4: Director Andrew Scott (reporting as Andy Blank Revocable Living Trust) purchased 288,000 shares of common stock and received 288,000 warrants on 09/19/2025 at a price of $1.25 per share/warrant bundle. After the transaction the reporting person beneficially owned 634,023 shares (direct/indirect holdings) and held warrants exercisable into 288,000 shares expiring 09/20/2027. The filing notes the shares are held in a revocable trust for which the reporting person is trustee. The Form 4 was signed by power of attorney on 09/23/2025.
Insider purchase reported for BioCardia, Inc. (BCDA). Peter Altman, the company's President, CEO and a director, purchased 48,000 shares of common stock at $1.25 per share on 09/19/2025 through a public offering that closed that day, and received 48,000 warrants exercisable at $1.25 expiring 09/20/2027. After the transaction Mr. Altman beneficially owned 216,762 shares of common stock and 143,612 derivative securities (warrants/options) on a direct basis. The Form 4 was signed under power of attorney on 09/23/2025.
BioCardia, Inc. filed an 8-K to report that it has had a positive preliminary clinical consultation with Japan’s Pharmaceutical and Medical Devices Agency (PMDA) regarding the CardiAMP Heart Failure Trial results previously provided to the agency.
The meeting was held to prepare for a formal clinical consultation on whether the trial data will be acceptable for submission of an application for product approval in Japan. BioCardia also furnished the related press release as an exhibit to this report.
Lincoln Alternative Strategies LLC reported beneficial ownership of 800,000 shares of BioCardia, Inc. common stock, representing 7.54% of the outstanding shares based on 10,608,734 shares outstanding as of September 19, 2025. The filing lists sole voting and dispositive power over all 800,000 shares and indicates the holder is organized in Delaware. The filing includes a certification that the securities were not acquired to change or influence control of the issuer. Contact and address details for the issuer and filer are provided in the statement.
BioCardia, Inc. completed a registered offering on September 19, 2025, selling 4,800,000 shares of common stock together with warrants to purchase up to 4,800,000 shares at a combined price of $1.25 per share and warrant, generating approximately $6.0 million in gross proceeds. Certain directors and executive officers purchased 734,400 shares and warrants for roughly $0.9 million. The company expects net proceeds of about $5.1 million after placement agent fees and offering expenses. Each warrant is exercisable at $1.25, immediately exercisable, and expires September 20, 2027, subject to customary anti-dilution adjustments and beneficial ownership exercise limits (default 4.99% or elective 9.99% with notice). The Purchase Agreements include customary representations, indemnities and closing conditions, and contain lock-up and variable-rate transaction restrictions through November 18, 2025 and March 19, 2026, respectively, which the placement agent may waive.
BioCardia is conducting a best-efforts primary offering of 4,800,000 shares of common stock, each sold together with a warrant to buy one additional share, at a combined price of $1.25 per share-and-warrant unit. Gross proceeds are expected to be $6.0 million, with approximately $5.1 million in net proceeds after fees and expenses if all securities are sold. The company expects to use the cash mainly for working capital and to advance its cell therapy programs and delivery partnering business.
After the offering, BioCardia expects 10,608,734 shares of common stock to be outstanding, excluding warrant exercises. The raise would move stockholders’ equity from a deficit to positive $3.2 million, helping address Nasdaq’s minimum equity requirement, and is expected to fund operations at current burn levels into the second quarter of 2026, though additional capital will still be needed.
BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants. The filing presents this as a Regulation FD disclosure, meaning the company is sharing this capital markets update broadly with investors. The press release is included as Exhibit 99.1, along with an Inline XBRL cover page data file listed as Exhibit 104.
BioCardia, Inc. filed a current report describing a communication about one of its clinical programs. The company furnished a press release announcing primary endpoint results from the open label roll-in cohort of its CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. The press release is included as Exhibit 99.1 and is treated as furnished, not filed, under securities law.
BioCardia, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the original registration statement unchanged and focuses on updating and organizing the exhibit list, including agreements related to prior mergers, equity incentive plans, various securities purchase and warrant agreements, indemnification and change of control arrangements for executives, leasing arrangements, and at-the-market and other offering agreements with financial firms. The filing also includes legal opinions, auditor consents, and technical XBRL documents, and is signed by the President and Chief Executive Officer and the Chief Financial Officer, along with the company’s directors under a power of attorney.